'Highly efficacious' shingles vaccine excluded from NIP

The vaccine's cost and long-term effectiveness remain in doubt, says the PBAC

A promising new shingles vaccine won't be included on the National Immunisation Program because of doubts surrounding its cost and long-term effectiveness, the Pharmaceutical Benefits Advisory Council says.